Given the downregulation of PD-L1 on the AT3 tumours, it was unsurprising that the addition of anti-PD-1 conferred no further benefit in the AT3 as well as the 4T1ch9 models (Fig. 3c). The gene discussed is PDCD1; the disease is neoplasm.